Asenapine: A Review in Schizophrenia

CNS Drugs

Volumn 30, Issue 7, 2016, Pages 655-666

  Plosker, Greg L ^a   Deeks, Emma D ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; GLUCOSE; HALOPERIDOL; LURASIDONE; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

AGRANULOCYTOSIS; AKATHISIA; ALLERGIC REACTION; ARTICLE; ASIAN; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERTRANSAMINASEMIA; HYPESTHESIA; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREATMENT DURATION; VOMITING; BIPOLAR DISORDER; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84976339024     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0363-2     Document Type: Article

References (60)

1. Rossler W, Salize HJ, van Os J, et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399–409.
2. Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–9.
3. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28(2):325–34.
4. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141.
5. Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am. 2007;30(3):323–38.
6. Cortese L, Bressan RA, Castle DJ, et al. Management of schizophrenia: clinical experience with asenapine. J Psychopharmacol. 2013;27(4 Suppl):14–22.
7. Villalta-Gil V, Vilaplana M, Ochoa S, et al. Neurocognitive performance and negative symptoms: are they equal in explaining disability in schizophrenia outpatients? Schizophr Res. 2006;87(1–3):246–53.
8. Miller BJ, Paschall CB 3rd, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatr Serv. 2006;57(10):1482–7.
9. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology. 2003;28(Suppl 1):9–26.
10. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
11. De Hert M, Yu W, Detraux J. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26:733–59.
12. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911.
13. Rado J, Janicak PG. Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. Drugs Aging. 2012;29(10):783–91.
14. Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–53.
15. Wang SM, Han C, Lee SJ, et al. Asenapine, blonanserin, iloperidone, lurasidone, and sertindole: distinctive clinical characteristics of 5 novel atypical antipsychotics. Clin Neuropharmacol. 2013;36(6):223–38.
16. Werner FM, Covenas R. Safety of antipsychotic drugs: focus on therapeutic and adverse effects. Expert Opin Drug Saf. 2014;13(8):1031–42.
17. Actavis Inc. Saphris (asenapine) sublingual tablets: US prescribing information. 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 13 Jun 2016.
18. 2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology. 1997;131(4):339–45.
19. Marston HM, Young JW, Martin FDC, et al. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology. 2009;206(4):699–714.
20. Elsworth JD, Groman SM, Jentsch DJ, et al. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology. 2012;62(3):1442–52.
21. Jardemark K, Marcus MM, Shahid M, et al. Effects of asenapine on prefrontal N-methyl-d-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse. 2010;64(11):870–4.
22. 2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse. 2012;66(7):650–60.
23. Tarazi FI, Moran-Gates T, Wong EHF, et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol (Oxf). 2010;24(3):341–8.
24. Oosterhof CA, El Mansari M, Blier P. Asenapine alters the activity of monoaminergic systems following its subacute and long-term administration: an in vivo electrophysiological characterization. Eur Neuropsychopharmacol. 2015;25(4):531–43.
25. Ohyama M, Kondo M, Yamauchi M, et al. Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model. Acta Neuropsychiatr. 2016. doi:10.1017/neu.2016.17.
26. Tarazi FI, Neill JC. The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opin Drug Discov. 2013;8(1):93–103.
27. Franberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology. 2008;196(3):417–29.
28. Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10(6):893–903.
29. Mandrioli R, Protti M, Mercolini L. Novel atypical antipsychotics: metabolism and therapeutic drug monitoring (TDM). Curr Drug Metab. 2015;16(2):141–51.
30. Gerrits M, de Greef R, Peeters P. Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Biopharm Drug Dispos. 2010;31(5–6):351–7.
31. Peeters P, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet. 2011;50(7):471–81.
32. Dubovsky SL, Frobose C, Phiri P, et al. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry. 2012;27(5):472–82.
33. Gerrits MG, de Greef R, Dogterom P, et al. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. J Clin Pharmacol. 2012;52(5):757–65.
34. Dogterom P, Schnabel PG, Timmer C, et al. Effect of carbamazepine on asenapine pharmacokinetics [abstract no. PII-44]. Clin Pharmacol Ther. 2008;83(Suppl 1):S55.
35. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492–500.
36. Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–15.
37. Kinoshita T, Bai Y-M, Kim J-H, et al. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology. 2016. doi:10.1007/s00213-016-4295-9.
38. Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014;13(6):803–30.
39. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762–84.
40. Pratts M, Citrome L, Grant W, et al. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatr Scand. 2014;130(1):61–8.
41. Szegedi A, Verweij P, Van Duijnhoven W, et al. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73(12):1533–40.
42. Friberg LE, de Greef R, Kerbusch T, et al. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther. 2009;86(1):84–91.
43. Leucht S, Zhao J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol. 2014;28(4):387–94.
44. Castle DJ, Jensen JKS. Management of depressive symptoms in schizophrenia: a pooled, post hoc analysis from the asenapine development program. Clin Schizophr Relat Psychoses. 2015;9(1):13–20.
45. Kane JM, Mackle M, Snow-Adami L, et al. A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment. J Clin Psychiatry. 2011;72(3):349–55.
46. Schoemaker J, Naber D, Vrijland P, et al. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder [erratum in Pharmacopsychiatry 2011;44:343]. Pharmacopsychiatry. 2010;43(4):138–46.
47. Schoemaker J, Stet L, Vrijland P, et al. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5):196–203.
48. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36–45.
49. Potkin SG, Phiri P, Szegedi A, et al. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res. 2013;150(2–3):442–9.
50. Gao K, Mackle M, Cazorla P, et al. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1145–57.
51. Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol. 2009;49:1297–308.
52. Chapel S, Hutmacher MM, Bockbrader H, et al. Comparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: case study of a thorough QT study of asenapine. Clin Pharmacol Ther. 2011;89(1):75–80.
53. Thomas JE, Caballero J, Harrington CA. The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol. 2015;13(5):681–91.
54. Kemp DE, Zhao J, Cazorla P, et al. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder. J Clin Psychiatry. 2014;75(3):238–45.
55. Cazorla P, Mackle M, Zhao J, et al. Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia. Neuropsychiatr Dis Treat. 2012;8:247–57.
56. De Hert M, Guiraud-Diawara A, Marre C. Comparison of metabolic syndrome incidence among schizophrenia patients treated with asenapine versus olanzapine [abstract no. 2584]. Eur Psychiatry. 2013;28(Suppl 1).
57. ® sublingual tablets 5 and 10 mg: Japanese prescribing information. 2016. http://www.meiji-seika-pharma.co.jp/medical/product/sycrest/pdf/sycrest_ATC.pdf. Accessed 13 Jun 2016.
58. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management (NICE clinical guideline 178). 2014. https://www.nice.org.uk/guidance/cg178. Accessed 13 Jun 2016.
59. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, 2nd edn. 2004. http://psychiatryonline.org. Accessed 13 Jun 2016.
60. Dixon L, Perkins D, Calmes C. American Psychiatric Association guideline watch (September 2009): practice guideline for the treatment of patients with schizophrenia. 2009. http://psychiatryonline.org. Accessed 13 Jun 2016.